Scarica l'app Stockscreener
2.70
5.88%
0.15
Dopo l'orario di chiusura:
2.71
0.010
+0.37%
Precedente Chiudi:
$2.55
Aprire:
$2.49
Volume 24 ore:
635.64K
Relative Volume:
0.79
Capitalizzazione di mercato:
$194.97M
Reddito:
-
Utile/perdita netta:
$-121.34M
Rapporto P/E:
-1.3476
EPS:
-2.0035
Flusso di cassa netto:
$-115.63M
1 W Prestazione:
+5.88%
1M Prestazione:
-18.18%
6M Prestazione:
+52.54%
1 anno Prestazione:
+150.00%
Intervallo 1D:
$2.49
$2.745
Intervallo di 1 settimana:
$2.17
$2.745
Portata 52W:
$0.8551
$3.60
Acumen Pharmaceuticals Inc Stock (ABOS) Company Profile
Nome
Acumen Pharmaceuticals Inc
Settore
Industria
Telefono
617-344-4190
Indirizzo
1210-1220 WASHINGTON STREET, NEWTON
Compare ABOS vs VRTX, REGN, ARGX, ALNY, INSM
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ABOS
Acumen Pharmaceuticals Inc
|
2.70 | 194.97M | 0 | -121.34M | -115.63M | -2.0035 |
VRTX
Vertex Pharmaceuticals Inc
|
438.71 | 111.45B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
761.85 | 80.54B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
746.42 | 46.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
318.85 | 42.29B | 3.71B | 313.75M | 465.38M | 2.2571 |
INSM
Insmed Inc
|
162.43 | 35.01B | 606.42M | -1.28B | -997.58M | -6.403 |
Acumen Pharmaceuticals Inc Stock (ABOS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-06-17 | Iniziato | Citigroup | Buy |
| 2024-07-26 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-07-20 | Ripresa | BofA Securities | Buy |
| 2023-05-18 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-07-15 | Iniziato | BTIG Research | Buy |
| 2022-06-30 | Iniziato | H.C. Wainwright | Buy |
| 2022-01-21 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2021-07-26 | Iniziato | BofA Securities | Neutral |
| 2021-07-26 | Iniziato | Credit Suisse | Outperform |
| 2021-07-26 | Iniziato | Stifel | Buy |
| 2021-07-26 | Iniziato | UBS | Buy |
Mostra tutto
Acumen Pharmaceuticals Inc Borsa (ABOS) Ultime notizie
Acumen Pharmaceuticals’ Earnings Call: Promise Amid Pressure - TipRanks
Acumen Pharmaceuticals (ABOS) loses 33.6% in 4 weeks, here's why a trend reversal may be around the corner - MSN
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2025 Earnings Call Transcript - Insider Monkey
[EFFECT] Acumen Pharmaceuticals, Inc. SEC Filing - Stock Titan
Acumen Pharmaceuticals (NASDAQ: ABOS) registers 10.83M resale shares - Stock Titan
Is Acumen Pharmaceuticals (ABOS) stock outpacing its medical peers this year? - MSN
ABOS Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
ABOS Forecast, Price Target & Analyst Ratings | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen targets ALTITUDE-AD Phase II readout in late 2026 while advancing EBD program with $36M funding - MSN
Acumen Pharmaceuticals (ABOS) Loses 33.6% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - finance.yahoo.com
Aug Final Week: Can Acumen Pharmaceuticals Inc reach resistance levels soon - baoquankhu1.vn
Is Acumen Pharmaceuticals (ABOS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Acumen Pharmaceuticals (NASDAQ:ABOS) Rating Increased to Hold at Wall Street Zen - MarketBeat
Acumen Pharmaceuticals files to sell 10.83M shares of common stock for holders - MSN
Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Acumen Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - finance.yahoo.com
12 Health Care Stocks Moving In Friday's Pre-Market Session - Benzinga
Acumen Pharmaceuticals Reports 2025 Financial Results and Advances Alzheimer’s Drug Pipeline with Phase 2 ALTITUDE-AD Study and Enhanced Brain Delivery Program - minichart.com.sg
10.8M Acumen shares registered for resale (NASDAQ: ABOS) - stocktitan.net
Acumen Pharmaceuticals Inc (ABOS) Q4 2025 Earnings Call Highlights: Strategic Advances Amid ... By GuruFocus - Investing.com Canada
Acumen Pharmaceuticals (NASDAQ: ABOS) details sabirnetug Alzheimer’s program and funding risks - Stock Titan
Acumen Updates Alzheimer’s Pipeline, Extends Cash Runway Into 2027 - TipRanks
Stifel reiterates Acumen Pharmaceuticals stock rating at buy By Investing.com - au.investing.com
Stifel reiterates Acumen Pharmaceuticals stock rating at buy - Investing.com
Acumen Pharmaceuticals 2025 Financial Review - AlphaStreet
Acumen Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Acumen Pharmaceuticals (NASDAQ:ABOS) Receives "Buy" Rating from BTIG Research - MarketBeat
Acumen Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
ABOS: ALTITUDE-AD phase II and EBD advances drive robust pipeline and financial momentum - TradingView
Acumen Pharmaceuticals (NASDAQ:ABOS) Announces Earnings Results, Beats Expectations By $0.09 EPS - MarketBeat
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements By Investing.com - Investing.com South Africa
Earnings call transcript: Acumen Pharmaceuticals Q4 2025 reveals strategic advancements - ca.investing.com
Acumen Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 - MarketScreener
ABOS: ALTITUDE-AD trial advances, EBD pipeline expands, and $35.75M raised for Alzheimer's innovation - TradingView
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating By Investing.com - Investing.com India
Acumen Pharmaceuticals Inc (NASDAQ:ABOS) Reports Narrower-Than-Expected Q4 Loss, Provides Key Clinical Update - ChartMill
Patterns Watch: What is the earnings history of Acumen Pharmaceuticals IncSell Signal & Free Growth Oriented Trading Recommendations - baoquankhu1.vn
Cantor Fitzgerald reiterates Acumen Pharmaceuticals stock rating - investing.com
Acumen Pharmaceuticals Reports Financial Results for the Year Ended December 31, 2025 and Business Highlights - Bitget
ACUMEN PHARMACEUTICALS ($ABOS) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Scheduled For March 26, 2026 - Benzinga
Acumen (NASDAQ: ABOS) deepens 2025 loss but extends cash runway toward key Alzheimer’s data - Stock Titan
BRIEF-Acumen Pharmaceuticals, Inc. FY Income From Operations USD -123.832 Million Vs. IBES Estimate USD -127.9 Million - TradingView
Alzheimer’s drug readout due in late 2026 as Acumen targets 2027 filing - Stock Titan
Acumen Pharmaceuticals, Inc. (Acumen Pharmaceuticals) recently officially released its annual financial report for the year ended December 31, 2025, and simultaneously reviewed the key business developments of the company over the past year. - Bitget
Acumen Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt - MarketScreener
Acumen Pharmaceuticals Inc expected to post a loss of 45 cents a shareEarnings Preview - TradingView
ABOS Technical Analysis | Trend, Signals & Chart Patterns | ACUMEN PHARMACEUTICALS INC (NASDAQ:ABOS) - ChartMill
Acumen Pharmaceuticals (ABOS) Projected to Post Earnings on Monday - MarketBeat
ABOS (Acumen Pharmaceuticals) PB Ratio : 1.74 (As of Mar. 23, 2026) - GuruFocus
Acumen Pharmaceuticals Inc Azioni (ABOS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.49%
1.47%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):